Scientific Posters from Neuroscience 2017

Charles River Poster Presentations

Neuroscience 2017 is a forum for Charles River scientists to showcase key findings from independent research and collaborative efforts with top scientists from across the globe. During this year’s meeting, Charles River scientists from multiple sites and scientific disciplines presented scientific posters either independently or collaboratively with our clients. Click on the title to view an electronic file of the poster.

Technologies

• Pharmacological MRI – In Vivo Imaging Platform for Pre-clinical CNS Drug Discovery (245.23/OO20)

  Artem Shatillo, Tuukka Miettinen, Janika Keinänen, Antti Nurmi
  Charles River, Kuopio, Finland

• Autoradiography Methodologies in CNS Research (716.12/VV31)

  Jussi Rytkönen, Teija Parkkari, Outi Kontkanen, Antti Nurmi, Tuulia Huhtala
  Charles River, Kuopio, Finland

• Imaging of Dopamine Transporter in Rodents Using PET and SPECT (756.09/M5)

  Tuulia Huhtala¹, Jussi Rytkönen¹, Pekka Poutiainen^{2, 3}, Raimo Pussinen¹, Teija Parkkari¹, Antti Nurmi^{1
  1}Charles River, Kuopio, Finland, ²A.I. Virtanen Institute for Molecular Medicine, University of Eastern Finland, Kuopio, Finland, ³Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Finland

• Neurological Findings in Aged Rats Using Translational Imaging Technologies: PET, SPECT and MRI (756.08/M4)

  Jussi Rytkönen¹, Pekka Poutiainen^{2, 3}, Teija Parkkari¹, Antti Nurmi¹, Tuulia Huhtala^{1
  1}Charles River, Kuopio, Finland, ²A.I. Virtanen Institute for Molecular Medicine, University of Eastern Finland, Kuopio, Finland, ³Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Finland

• Preclinical PET Imaging of CNS Diseases in Rodent Models (756.10/M6)

  Jussi Rytkönen¹, Pekka Poutiainen^{2, 3}, Artem Shatillo¹, Kimmo Lehtimäki¹, Karoliina Soininen¹, Tuulia Huhtala^{1
  1}Charles River, Kuopio, Finland, ²A.I. Virtanen Institute for Molecular Medicine, University of Eastern Finland, Kuopio, Finland, ³Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Finland

• Monitoring of Corticostriatal Synaptic Plasticity with an Implantable Microbiosensor Device to Understand Cognitive Performance in Neurodegenerative Diseases

  Nicholas Moore¹, Carlos A. Cordeiro^{1, 2}, T. Koster¹, L. Kuhl¹, Joost HA Folgering¹, Thomas IF Cremers^{1,2
  1}Brains On-Line, a Charles River company, Groningen, the Netherlands, ²University of Groningen, Dept. of Pharmaceutical Analysis, Groningen, the Netherlands

Parkinson's Disease

• Administration of AAV Alpha-synuclein to C57BL6/J and G2019s Mice (048.18/V4)

  Robert Hodgson¹, Jere Kurkipuro¹, Teija Parkkari¹, Terina Martinez², Matthew Fell³, Taneli Heikkinen¹, Lynn Hyde³, Antti Nurmi¹, Thomas Lanz⁴, Antonia Stepan⁴, Marco Baptista^{2
  1}Charles River, Kuopio, Finland; ²Michael J Fox Foundation, New York, NY; ³Merck & Co. Inc., Boston, MA; ⁴Pfizer Inc, Cambridge, MA

• Administration of AAV Alpha-synuclein in SD and G2019S-LRRK2 Rats (048.19/V5)

  Robert Hodgson¹, Teija Parkkari¹, Terina Martinez², Matthew Fell³, Laura Koistinen¹, Tuulia Huhtala¹, Jussi Rytkönen¹, Pekka Poutiainen^5,6, Jere Kurkipuro¹, Lynn Hyde³, Antti Nurmi¹, Thomas Lanz⁴, Antonia Stepan⁴, Marco Baptista^{2
  1}Charles River, Kuopio, Finland; ²Michael J Fox Foundation, New York, NY; ³Merck & Co. Inc., Boston, MA; ⁴Pfizer Inc, Cambridge, MA; ⁵A.I. Virtanen Institute for Molecular Medicine, University of Eastern Finland, Kuopio, Finland; ⁶Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Finland

• Behavioral Consequences of Administration of AAV Alpha-synuclein to Rat (048.20/V6)

  Robert Hodgson¹, Teija Parkkari¹, Terina Martinez², Matthew Fell³, Laura Koistinen¹, Timo Bragge¹, Lynn Hyde³, Antti Nurmi¹, Thomas Lanz⁴, Antonia Stepan⁴, Marco Baptista^{2
  1}Charles River, Kuopio, Finland; ²Michael J Fox Foundation, New York, NY; ³Merck & Co. Inc., Boston, MA; ⁴Pfizer Inc, Cambridge, MA

• Characterization of Alpha-synuclein and Neurotransmitters During the Sleep Wake Cycle of a Parkinson’s Disease Model Expressing Human Wild-Type Alpha-synuclein (048.17/V3)

  L. Yu, A. Rassoulpour, H. Janssens, M. van der Hart, T. Cremers
  Brains On-Line, a Charles River Company, South San Francisco, CA

• MPTP Mouse Model of Parkinson's Disease – Imaging Modalities for Metabolic, Anatomical and ¹H-spectroscopic Changes (575.13/W2)

  Kimmo Lehtimäki, Jere Kurkipuro, Jukka Puoliväli, Tuulia Huhtala, Antti Nurmi
  Charles River, Kuopio, Finland

• Assessment of Haloperidol-induced Tremulous Jaw Movement in Rats Using Loose Restraint and a Video Recording System (300.10/U5)

  Robert Hodgson, Antti Nurmi, Laura Koistinen
  Charles River, Kuopio, Finland

• Assay Development and Validation of a High Content-based High-throughput Assay to Measure α-Synuclein Aggregation in Dopaminergic Human Neurons Differentiated In Vitro

  Folkert Verkaar¹, Terina Martinez², Astrid Jensen¹, Toni Wolinsky¹, David F. Fischer¹, Jeroen DeGroot¹ and Blandine Mille-Baker^{1
  1}Charles River Laboratories, Darwinweg 24, 2333 CR, Leiden, The Netherlands, ²The Michael J. Fox Foundation for Parkinson’s Research, 498 Seventh Avenue, NY 10018, New York, USA

• Evaluation of Constipation Endpoints in MPTP-treated Mice (133.25/W19)

  Ramio Pussinen, Antti Nurmi, Robert Hodgson
  Charles River, Kuopio, Finland

• The Potent and Selective A_2A Receptor Antagonist, Preladenant, Produces a Robust Effect in L-dopa Induced Turning, but Only Modest Efficacy in the Cylinder Assay in Unilaterally 6-OHDA Lesioned Rats

  AC Morse¹, R Hodgson², RO Pussinen², J Korkalainen², M Suhonen², AJ Nurmi², JA VIivian^{3
  1}Neuropharm., Dart NeuroScience, San Diego, CA; ²Charles River Discovery, Kuopio, Finland; ³Dart Neurosci., San Diego, CA

Alzheimer's Disease

• Characterization of Tau Expressing P301S Mouse Model for Tauopathy – Longitudinal Brain Structural and Metabolic Profile (046.08/Q4)

  Jukka Puoliväli, Kimmo Lehtimäki, Tuulia Huhtala, Jussi Rytkönen, Antti Nurmi
  Charles River, Kuopio, Finland

Huntington's Disease

• Deficient Object Location/Paired Associates Learning in Q175 KI Mouse Model of Huntington’s Disease (575.05/V20)

  Maksym V. Kopanitsa, Tuukka Piiponniemi, Teija Parkkari, Antti Nurmi
  Charles River, Kuopio, Finland

Multiple Sclerosis

• Deficits in Touchscreen-based Operant Tasks and Fear Conditioning Memory in the Cuprizone Model of Multiple Sclerosis (303.21/X13)

  Antti Nurmi¹, Maksym V. Kopanitsa¹, Kimmo Lehtimäki¹, Markku E. Forsman¹, Ari Suhonen¹, Juho Koponen¹, Avia Merenlender-Wagner², Joel Kaye², Aric Orbach^{2
  1}Charles River, Kuopio, Finland; ²Teva Pharmaceutical Industries Ltd., Netanya, Israel

• Immunophenotyping and Characterization of PLP and MOG Induced Relapsing/Remitting and Chronic Mouse Models of Experimental Autoimmune Encephalomyelitis (303.22/X14)

  Tuulia Huhtala, Jere Kurkipuro, Laura Koistinen, Maria Vihma, Anniina Oksman, Leena Tähtivaara, Antti Nurmi
  Charles River, Kuopio, Finland

Pain

• Analgesics Assessment in Rat MIA Model Using the Bioseb Automated Dynamic Weight Bearing System

  Harun Rashid, Julie Douville and Rana Samadfam
  Charles River, Montreal

Learn How We Can Support You Through The Entire Neuroscience Research Process